Medlock Holmes enters a vast radiological observatory where the human brain can be examined without ever being opened.
The earliest instruments are crude. Old computed tomography images reveal enlarged ventricles-dark chambers within the brain that seem wider in people with schizophrenia. The finding is important, but it is not specific enough to solve the case.
Then the observatory changes.
Magnetic resonance imaging arrives.
For the first time, Holmes can examine living grey matter, white matter, cortical thickness, hippocampal volume, and the delicate pathways connecting distant brain regions. Yet the abnormalities he discovers are rarely dramatic. They are small, distributed, and different from one person to another.
Large studies reveal recurring patterns. The lateral ventricles are often enlarged. The hippocampus, amygdala, thalamus, nucleus accumbens, and overall intracranial volume tend to be smaller. Cortical thinning is particularly evident in frontal, temporal, insular, and anterior cingulate regions. These findings confirm that schizophrenia is associated with measurable brain differences, but none can diagnose an individual patient.
Holmes then follows the illness across time.
Some structural differences are already present in people at clinical or familial risk. Around the transition to psychosis, cortical thinning and ventricular expansion may accelerate, particularly in frontal regions. The greatest grey- and white-matter changes often occur during the first few years after onset, suggesting that early psychosis is a particularly dynamic phase.
In chronic illness, brain structure continues to reflect the combined influence of neurodevelopment, ageing, physical health, substance use, recurrent episodes, and treatment exposure. Some studies suggest accelerated age-related loss of grey and white matter, although the pattern appears to slow later in life. Medication effects are complex: antipsychotics may contribute to some grey-matter changes while potentially protecting aspects of white-matter integrity.
The investigation then moves from tissue volume to connectivity.
Diffusion MRI allows Holmes to trace white-matter pathways by measuring the movement of water along axons. Across schizophrenia, fractional anisotropy is commonly reduced, particularly in the corpus callosum, corona radiata, cingulum, uncinate fasciculus, superior longitudinal fasciculus, and other frontotemporal connections.
These abnormalities support the dysconnectivity hypothesis: schizophrenia may arise not only from changes within individual regions, but from impaired communication between them.
Newer techniques refine the picture further. Free-water imaging may distinguish extracellular changes-possibly related to inflammation-from abnormalities within white-matter tissue itself. Neurite imaging can examine axonal density and organisation. Normative modelling compares each person with an expected range rather than merely comparing one diagnostic group with another.
This reveals a crucial truth.
The average schizophrenia brain does not necessarily represent any one individual with schizophrenia. Many people fall within normal structural ranges in most regions, while smaller subgroups show distinct patterns of deviation.
By the end of the investigation, Holmes understands why structural imaging has transformed research without yet becoming a routine diagnostic test.
The scans reveal that schizophrenia is unquestionably associated with the brain.
But they also reveal its heterogeneity.
There is no single anatomical fingerprint.
Instead, structural imaging offers a map of vulnerability, transition, progression, resilience, and possible biological subtypes.
The mystery is no longer whether the brain is involved.
The mystery is how many different structural pathways can lead to the same clinical destination.
Key Takeaways
Structural imaging established that schizophrenia is associated with measurable brain abnormalities.
Computed tomography first demonstrated enlarged lateral ventricles in schizophrenia.
MRI provides superior visualisation of grey matter, white matter, cortical structure, and subcortical anatomy without ionising radiation.
Structural abnormalities are generally subtle, distributed, and nonspecific.
Enlarged lateral ventricles remain one of the most replicated findings.
Common subcortical findings include reduced hippocampal, amygdala, thalamic, nucleus accumbens, and intracranial volumes.
Cortical thinning is particularly evident in frontal, temporal, insular, and anterior cingulate regions.
Large multisite collaborations such as ENIGMA have improved statistical power and reproducibility.
Grey-matter changes may be present before psychosis and become more pronounced around illness onset.
The most rapid structural changes often occur during the first few years after a first psychotic episode.
Clinical high-risk individuals who transition to psychosis may show accelerated frontal cortical thinning and ventricular expansion.
Unaffected relatives may show milder structural differences, suggesting inherited vulnerability.
Chronic schizophrenia may be associated with accelerated age-related grey- and white-matter change.
Antipsychotic medication may influence brain structure, but medication effects are complex and difficult to separate from illness effects.
Diffusion MRI identifies widespread abnormalities in white-matter microstructure.
Frequently implicated tracts include the corpus callosum, cingulum, corona radiata, uncinate fasciculus, and superior longitudinal fasciculus.
Reduced fractional anisotropy supports the concept of impaired structural connectivity.
Free-water imaging may help distinguish extracellular inflammatory changes from white-matter tissue pathology.
Normative modelling shows that group averages conceal substantial individual heterogeneity.
Structural imaging cannot currently diagnose schizophrenia in an individual patient.
Future progress will depend on longitudinal, multimodal, biologically informed, and precision-medicine approaches.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.